Molinelli, Chiara
Jacobs, Flavia
Nader-Marta, Guilherme
Borea, Roberto
Scavone, Graziana
Ottonello, Silvia
Fregatti, Piero
Villarreal-Garza, Cynthia
Bajpai, Jyoti
Kim, Hee Jeong
Puglisi, Silvia
de Azambuja, Evandro
Lambertini, Matteo
Funding for this research was provided by:
Università degli Studi di Genova
Article History
Accepted: 7 February 2024
First Online: 13 March 2024
Compliance with Ethical Standards
:
: Chiara Molinelli reports fees from Novartis and Eli Lilly, travel grants from Gilead and Menarini (all outside the submitted work). Guilherme Nader-Marta reports meeting/travel grants from Roche, Bayer and AstraZeneca (all outside the submitted work). Evandro de Azambuja reports honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs, Pierre Fabre, Lilly, Astra-Zeneca, MSD, Gilead Sciences; travel grants from Roche/GNE and Astra-Zeneca; research grant to his institution from Roche/GNE, Astra-Zeneca, and GSK/Novartis, Gilead Sciences (all outside the submitted work). He’s ESMO director of Membership 2023–2024 and BSMO President 2023–2026. Matteo Lambertini reports advisory role for Roche, Lilly, Novartis, Astrazeneca, Pfizer, Seagen, Gilead, MSD and Exact Sciences and speaker honoraria from Roche, Lilly, Gilead, Novartis, Pfizer, Sandoz, Libbs, Daiichi Sankyo, Knight and Takeda, Travel Grants from Gilead, Roche and Daiichi Sankyo, and research support (to the Institution) from Gilead outside the submitted work. The other authors made no disclosures.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Not applicable.